EUCTR2006-001898-25-DK进行中（未招募）不适用
DORADO - Fixed Doses of Darusentan as Compared to Placebo in ResistantHypertensionA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan inSubjects with Resistant Systolic Hypertension Receiving Combination Therapy withThree or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311) - DORADO
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 352
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects must be competent to provide written informed consent
- •- Aged 35 to 80 years
- •- Subjects must have resistant systolic hypertension consistent with current clinical guidelines for the treatment of hypertension. Subjects with diabetes and/or CKD must have an average sitting SBP of =130 mmHg and all other subjects must have an average sitting SBP =140 mmHg at Screening.
- •- Subjects must be receiving, and adhering to, full doses of appropriate guideline-recommended antihypertensive drugs from three classes of antihypertensive agents, including a diuretic.
- •- Subjects must have a BMI of 20 to 40 kg/m2, inclusive, at Screening.
- •- Subjects must have an Egfr of = 30 MI/min/1.73m2 at Screening.
- •- Female subjects must be of non-childbearing potential
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Average sitting systolic blood pressure =180 mmHg or diastolic blood pressure =110 mmHg
- •- Serum ALT or AST =2X ULN
- •- Subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident (CVA) within 6 month; or sick sinus syndrome or second or third degree atrioventricular block, atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia
- •- Implanted pacemakers or implanted cardioverter defibrillator (ICD)
- •- Symptomatic CHF requiring treatment
- •- Hemodynamically significant valvular heart disease
- •- Type I diabetes mellitus
- •- Hemodialysis or peritoneal dialysis; or history of renal transplant
- •- Diagnosis or recurrence of malignancy within the past 3 years
- •- Sleep apnea, unless a recent sleep study demonstrates arterial oxygen saturation >90%
- •- Subjects who perform alternating shift or night work
- •- Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening
研究者
相似试验
进行中（未招募）
1 期
DORADO - Fixed Doses of Darusentan as Compared to Placebo in ResistantHypertensionA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan inSubjects with Resistant Systolic Hypertension Receiving Combination Therapy withFour or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311)DORADO - Dosis fijas de darusentán en comparación con placebo en la hipertensión arterial resistenteEstudio en fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de dosis fijas de darusentán en sujetos con hipertensión sistólica resistente tratados con una combinación de cuatro o más antihipertensivos, incluido un diurético. - DORADOResistant hypertensionLa hipertensión arterial resistenteMedDRA version: 9.1Level: LLTClassification code 10038274Term: Refractory hypertensionEUCTR2006-001898-25-ESMyogen, Inc.352
进行中（未招募）
不适用
DORADO - Fixed Doses of Darusentan as Compared to Placebo in ResistantHypertensionA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311) - DORADOResistant hypertensionEUCTR2006-001898-25-DEGilead Sciences Inc.352
进行中（未招募）
1 期
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311) - DORADOMedDRA version: 8.1 Level: LLT Classification code 10038274 Term: Refractory hypertensionResistant hypertensionEUCTR2006-001898-25-GBGilead Sciences, Inc.352
进行中（未招募）
不适用
DORADO - Fixed Doses of Darusentan as Compared to Placebo in ResistantHypertensionA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan inSubjects with Resistant Systolic Hypertension Receiving Combination Therapy withThree or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311) - DORADOResistant hypertensionMedDRA version: 8.1Level: LLTClassification code 10038274Term: Refractory hypertensionEUCTR2006-001898-25-SEGilead Sciences, Inc.352
进行中（未招募）
不适用
DORADO-Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four of More Antihypertensive Drugs, Including a Diuretic - DORADOEUCTR2006-001898-25-ITGilead Colorado, Inc.352